1M.B. Ch. B.-FIB.M.S. K, Kirkuk General Hospital, Kirkuk Health Directorate, Kirkuk City, Iraq
2Ph. D. Medical Microbiology, Medical Lab Consultant, Children Hospital, Kirkuk Health Directorate, Kirkuk City. Iraq
A cross-sectional study was carried out in Kirkuk city from of November 2017 to March 2018. The number of breast cancer women under study were 55 women whose ages were between 30–70 years old. These patients admitted to Kirkuk oncology center. The control group who were matched to the breast cancer patients studied, included 35 unaffected women and their ages were between 30–75 years old. These women presented Kirkuk General Hospital Four ml of blood was collected by vein puncture using Vacutainer tubes from each patient enrolled in this study for determination the level of IL-6 and IL-10 by using ELISA. The study showed that the highest mean level of IL-1 beta was found in women with breast cancer comparing with healthy control women (36.92±11.1 v.s. 10.1±3.7 pg/ml) (P: ≤0.05). The highest mean level of Il-6 was found in BC women comparing with control (97.13±14.7v.s. 22.13±6.91 pg/ml) (P: ≤0.05). The study showed that the highest mean level of IL-1 beta was found in women with breast cancer in the first stage of disease (33.2±9.1 pg/ml) and the level was still decreased to be the lowest level in the stage IV of breast cancer (20.18±2.9 pg/ml), the result was significant (P: ≤0.05). The study showed that the highest mean level of IL-6 was found in women with breast cancer in the first stage of disease (92.1±15.8 pg/ml) and the level was still decreased to be the lowest level in the stage IV of breast cancer (67.9±9.81 pg/ml), the result was significant (P: ≤0.05) It was concluded that there was a highly significant relation of IL-1 beta and IL-6 with breast cancer and especially in first stage of disease
Breast cancer, interleukin-1, interleukin-6
